Lipids in Atherosclerosis

The role of oxidized lipids in cardiovascular diseases (CVD) has been investigated over the last three decades extensively. A number of studies have been carried out on the mechanisms, and pathways leading to the arterial atherosclerosis.

Lipid abnormalities play a critical role in the development of atherosclerosis.[3] Early experiments in animals demonstrated accelerated atherosclerosis with a high-cholesterol diet. This was followed by epidemiologic studies conducted in countries around the world that showed an increasing incidence of atherosclerosis when serum cholesterol concentrations were elevated.

Atherosclerosis is the leading cause of death in North America and within the next two decades will be the leading cause worldwide. Atherosclerosis is characterized by vascular obstruction from the deposits of plaque, resulting in reduced blood flow. Plaque rupture and the consequent thrombosis may lead to sudden blockage of the arteries and cause heart attack. High serum lipid levels, especially the elevated level of low-density lipoproteins (LDL), have been shown to be strongly related to the development of atherosclerosis. It is generally accepted that atherosclerotic lesions are initiated via an enhancement of LDL uptake by monocytes and macrophages. In the liver, uptake of plasma LDL is mediated via specific LDL receptors, but a scavenger receptor system is employed by macrophages. Plasma LDL must be modified prior to uptake by macrophages.

Relevant Conferences

2nd  International Conference on Enzymology and Molecular Biology, March 20-21, 2017, Rome, Italy; 8th International Conference and Exhibition on Metabolomics & Systems Biology, May 08-10, 2017 Singapore; 2nd International Conference on Biochemistry September 28-29, 2017 Dubai, UAE; 9th International Conference on Bioinformatics October 23-24, 2017 Paris, France; 9th International Conference and Expo on Proteomics October 23-25, 2017 Paris, France; Third World Congress of Clinical Lipidology, February 10 -12, 2017 Brisbane, Australia; 15th Eurofed Lipid Congress: Oil, Fats and Lipids: New Technologies and Applications for a Healthier Life, August 27 – 30, 2017, Uppsala, Sweden; Fatty Acids and Lipids - Chemistry and Analysis Course, February 23 - 24, 2017, Dundee, Scotland; Keystone Symposia on Molecular and Cellular Biology: Lipidomics and Bioactive Lipids in Metabolism and Disease, February 26 - March 2, 2017, Tahoe City, California, USA; XX Lipid Meeting Leipzig, December 7 – 9, 2017, Leipzig, Germany; NLA Scientific Sessions – 2017, May 18-21, 2017, Philadelphia, PA.

  • Atherosclerotic cardiovascular events (ASCVE)
  • Familial hypercholesterolaemia (FH)
  • Elevated levels of LDL cholesterol and apolipoprotein B (apoB)
  • Plaque attacks
  • Cerebrovascular disease
  • Transient ischemic attacks (TIAs)
  • Peripheral artery disease
  • Angiography
  • Stenting
  • Angioplasty
  • Angina
  • Aspirin
  • Coronary heart disease (CHD)
  • Carotid artery disease
  • Chronic kidney disease
  • Arteriosclerosis
  • Hardening of the arteries
  • Coronary microvascular disease (MVD)
  • EKG (Electrocardiogram)
  • Ankle/Brachial Index
  • Echocardiography
  • Computed tomography scan
  • Ischemia

Related Conference of Lipids in Atherosclerosis

February 12-13, 2018

Glycobiology Biochem Conference 2018

Paris, France
September 17-18, 2018

34th International Conference on Chemical Biology & Radiation Therapy

San Diego, California
August 27-28, 2018

5th International Conference on Glycobiology

Toronto, Canada
September 17-19, 2018

4th Glycobiology World Congress

Rome, Italy
September 24-26, 2018

14th International Conference on Structural Biology

Berlin, Germany
November 29-30, 2018

Bioinformatics Congress 2018

Dublin, Ireland

Lipids in Atherosclerosis Conference Speakers

Recommended Sessions

Related Journals

Are you interested in